aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given an average recommendation of “Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.20.

Several equities analysts have recently weighed in on ATYR shares. Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Wednesday, June 4th. Finally, Wells Fargo & Company lifted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, June 20th.

Institutional Investors Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new stake in aTyr Pharma during the second quarter valued at $226,000. Thoroughbred Financial Services LLC bought a new stake in aTyr Pharma during the second quarter worth about $1,068,000. Creative Planning bought a new stake in aTyr Pharma during the second quarter worth about $74,000. Police & Firemen s Retirement System of New Jersey bought a new stake in aTyr Pharma during the second quarter worth about $101,000. Finally, Geode Capital Management LLC lifted its stake in aTyr Pharma by 126.1% during the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock worth $10,639,000 after purchasing an additional 1,170,276 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

Shares of NASDAQ ATYR opened at $5.61 on Tuesday. The stock has a market cap of $549.72 million, a PE ratio of -7.01 and a beta of 0.94. aTyr Pharma has a fifty-two week low of $1.67 and a fifty-two week high of $7.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. The stock has a fifty day moving average of $5.36 and a 200-day moving average of $4.14.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Equities research analysts anticipate that aTyr Pharma will post -0.91 earnings per share for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.